ReviewStem cells international2025
Epigenetic Mechanisms, Assessment and Therapeutics of Epidermal Stem Cells in Skin Aging.
Review in Stem cells international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetic Mechanisms, Assessment and Therapeutics of Epidermal Stem Cells in Skin Aging.Stem cells international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin aging is a multifaceted biological process driven by genetic and environmental factors, in which epidermal stem cells (EpSCs) decrease in number and decline in function. Emerging evidence indicates that epigenetic modifications play a crucial regulatory role in the aging process. Therefore, elucidating the epigenetic mechanisms in aging will provide novel avenues for developing strategies to delay aging. In this review, we explore the epigenetic mechanisms regulating EpSCs function, namely DNA methylation (DNAm), histone modifications, noncoding RNA, and their dysregulation and the resulting series of manifestations during aging. Furthermore, we introduce epigenetic clocks such as Horvath's and the skin-specific VisAgeX to quantify these age-related changes, which provide precise biomarkers of biological age, enabling the assessment of both aging progression and therapeutic outcomes. Finally, we summarize emerging interventions targeting these epigenetic disruptions. Advancing these epigenetic modulations holds significant potential for cutaneous antiaging and fostering innovative dermatological treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.